First boy gets Duchenne gene edit in Precision BioSciences (DTIL) trial
Rhea-AI Filing Summary
Precision BioSciences, Inc. (DTIL) reported that the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy (DMD). The first dosing occurred at Arkansas Children’s Hospital, a specialized Duchenne care center.
PBGENE-DMD uses the company’s ARCUS® platform to excise exons 45-55 of the dystrophin gene via two ARCUS nucleases delivered in a single AAV, aiming to restore a near full-length functional dystrophin protein. The trial is enrolling ambulatory boys aged 2–7 with mutations between exons 45 and 55, a group representing up to 60% of boys with DMD, with initial safety data expected by year-end 2026.
Positive
- First patient dosed in Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, marking a key first-in-patient clinical milestone for Precision BioSciences’ in vivo gene-editing platform.
- FUNCTION-DMD targets ambulatory DMD patients aged 2–7 with exon 45–55 mutations, potentially applicable to up to 60% of boys with DMD, indicating a large addressable patient subset.
- PBGENE-DMD benefits from multiple FDA incentives, including Orphan Drug Designation and Fast Track designation, and is eligible for a Priority Review Voucher under the Rare Pediatric Disease program if successfully approved.
Negative
- None.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
DMD patients in U.S.: approximately 15,000 patients
Target mutation coverage: up to 60% of boys with DMD
Patient age range: 2 to 7 years
+4 more
7 metrics
DMD patients in U.S.
approximately 15,000 patients
Estimated U.S. Duchenne muscular dystrophy prevalence cited for PBGENE-DMD program
Target mutation coverage
up to 60% of boys with DMD
Proportion of boys with DMD having mutations between exons 45 and 55 targeted by FUNCTION-DMD
Patient age range
2 to 7 years
Ambulatory DMD patients’ age range eligible for enrollment in Phase 1/2 FUNCTION-DMD
Orphan Drug Designation date
July 2025
Month and year FDA granted Orphan Drug Designation to PBGENE-DMD
Fast Track designation date
February 2026
Month and year FDA granted Fast Track designation to PBGENE-DMD
Rare Pediatric Disease PRV law date
February 3, 2026
Date Rare Pediatric Disease program was signed into law as part of Consolidated Appropriations Act of 2026
Initial safety data timing
by year-end 2026
Expected timing for initial safety data readout from FUNCTION-DMD trial
Key Terms
Orphan Drug Designation, Fast Track designation, Priority Review Voucher, ARCUS nucleases, +2 more
6 terms
Orphan Drug Designation regulatory
"PBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025."
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track designation regulatory
"PBGENE-DMD received Fast Track designation from the FDA in February 2026."
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Priority Review Voucher regulatory
"The PBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the Rare Pediatric Disease program."
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
ARCUS nucleases technical
"By employing two complementary ARCUS nucleases in a single AAV, PBGENE-DMD excises exons 45-55."
AAV technical
"two complementary ARCUS nucleases in a single AAV to excise exons 45-55 of the dystrophin gene"
AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.
in vivo gene editing technical
"a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies"
In vivo gene editing is a medical technique that changes a patient’s DNA directly inside their body, using tools that find and alter specific genes without removing cells for outside manipulation. For investors it matters because it promises one-time or long-lasting treatments for genetic diseases, creating high potential value but also carrying regulatory, safety and manufacturing risks similar to performing delicate repairs on wiring while the house is occupied.
FAQ
What did Precision BioSciences (DTIL) announce regarding its DMD program?
Precision BioSciences announced that the first patient has been dosed in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, an in vivo gene-editing therapy designed to restore near full-length dystrophin in boys with Duchenne muscular dystrophy.
What is PBGENE-DMD and how does it work for DMD patients?
PBGENE-DMD is a wholly owned in vivo gene-editing program using two ARCUS nucleases in a single AAV to excise exons 45–55 of the dystrophin gene, aiming to enable the body to produce a near full-length, functional dystrophin protein from the patient’s own gene.
Which patients are being enrolled in Precision BioSciences’ FUNCTION-DMD trial (DTIL)?
The Phase 1/2 FUNCTION-DMD study enrolls ambulatory boys aged 2–7 with Duchenne muscular dystrophy who have mutations between exons 45 and 55 of the dystrophin gene, a group representing up to 60% of boys with DMD.
When does Precision BioSciences (DTIL) expect initial data from the FUNCTION-DMD trial?
Precision BioSciences states that initial safety data from the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD are expected by year-end 2026, subject to trial progress and data collection.
What regulatory designations has PBGENE-DMD received according to Precision BioSciences (DTIL)?
PBGENE-DMD received Orphan Drug Designation from the FDA in July 2025 and Fast Track designation in February 2026. The program is also eligible for a Priority Review Voucher under the Rare Pediatric Disease program if it achieves approval.
How large is the Duchenne muscular dystrophy population targeted by PBGENE-DMD?
Precision BioSciences notes that Duchenne muscular dystrophy affects approximately 15,000 patients in the U.S., and mutations between exons 45 and 55 account for up to 60% of affected boys, the group targeted by PBGENE-DMD.
AI-generated analysis. How Rhea-AI works. Not financial advice.
